Donor-Derived 19-28z CAR T cells following Allogeneic Transplant for the Treatment of CD19 Malignancies

Inclusion Criteria

• Acute lymphoblastic leukemia (ALL) in second remission or greater (>= complete response 2 [CR2])
• Chronic lymphocytic leukemia (CLL): * High risk in any remission status as defined by 17p deletion or Richter’s transformation, or * All other patients eligible after at least 2 lines of standard or investigational chemotherapy
• Non-Hodgkin Lymphoma (B-NHL): * Refractory or stable disease to last line of therapy per International Congress on Medical Librarianship (ICML) 2014. Patients should have at least 2 lines of prior therapy; * Relapsed disease in patients who are not candidates for autologous transplant
• Karnofsky performance status (KPS) >= 70%
• Patients must have CD19 expression (by any detection method) demonstrated on their malignant cells at the time of enrollment on the protocol
• Patients relapsed after prior CD19 CAR T cell or blinatumomab are eligible for enrollment as long as CD19 expression is still prese on the malignant cells
• Patients who have a matched related donor willing to donate hematopoietic stem cells (HSC) for allograft and peripheral blood mononuclear cell (PBMC) for CAR T cell generation
• Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 50%
• < 3 x upper limit of normal (ULN) alanine aminotransferase (ALT) and < 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia
• Serum creatinine < 1.3 mg/dl or if serum creatinine is outside the normal range, then creatinine clearance (CrCl) > 60 ml/min (measured or calculated/estimated)
• Asymptomatic or if symptomatic, carbon monoxide diffusing capability (DLCO) > 50% of predicted (corrected for hemoglobin)
• Negative serum pregnancy test for women of child-bearing potential is required

Exclusion Criteria

• Active and uncontrolled infection at time of transplantation. Please note that patients being actively treated for a viral reactivation may be enrolled on the protocol at the discretion of the investigators
• Patients who have undergone a prior allogeneic or autologous stem cell transplant within the previous six months
• Pregnant or breast feeding
• Human immunodeficiency virus (HIV) infection
• Progressive disease at time of transplant
• Patients with known autoimmune disease
• Patients with active or clinically significant neurological disorders, such as seizure disorders